David Knorr

7PUBLICATIONS
48CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)AutoimmunityCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Dec 26, 2023
FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment.

David A Knorr, Lucas Blanchard, Rom S Leidner

|Feb 08, 2023
Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.

Scott Parker, Charlotte McDowall, Luis Sanchez-Perez

|Jul 28, 2022
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine.

Ramin Sedaghat Herati, David A Knorr, Laura A Vella

|Jun 03, 2022
Central Diabetes Insipidus Induced by Acute Myeloid Leukemia with DNMT3A Mutation.

Priyanka Lakshmanan, Heena Asnani, David Knorr

|May 20, 2021
Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer.

Christopher S Garris, Jeffrey L Wong, Jeffrey V Ravetch

|May 14, 2021
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.

Lindsey E Roeker, David A Knorr, Meghan C Thompson

Pageof 2